Kerri Fitzgerald

DocwireNews

A&nbsp;proof-of-concept&nbsp;study&nbsp;published in&nbsp;Nature&nbsp;found that&nbsp;there&nbsp;may be identifiable mutations&nbsp;in healthy individuals who are at high risk of developing acute myeloid leukemia (AML), and people may carry this mutation in the blood for years before disease detection.&nbsp;The researchers used&nbsp;data from the&nbsp;European Prospective Investigation into Cancer and Nutrition study, which started enrolling patients in&nbsp;1992&nbsp;from 10 European countries and followed the 521,000 patients for almost 15 years.&nbsp;&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Online <a href="https://twitter.com/Nature?ref_src=twsrc%5Etfw">@nature</a> Prediction of acute myeloid leukaemia risk in healthy individuals <a href="https://t.co/mlzV0eVR6Y">https://t.co/mlzV0eVR6Y</a> <a href="https://t.co/CbiSc4wPvL">pic.twitter.com/CbiSc4wPvL</a>
&mdash; Nature Genetics (@NatureGenet) <a href="https://twitter.com/NatureGenet/status/1017430943395729409?ref_src=twsrc%5Etfw">July 12, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>The researchers&nbsp;used&nbsp;deep sequencing to analyze genes that are recurrently mutated in AML to distinguish between&nbsp;those at high risk of developing AML&nbsp;versus those with&nbsp;benign&nbsp;age-related clonal hematopoiesis&nbsp;(ARCH).<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Prediction of acute myeloid leukaemia risk in healthy individuals <a href="https://twitter.com/hashtag/ArtificialIntelligence?src=hash&amp;ref_src=twsrc%5Etfw">#ArtificialIntelligence</a> <a href="https://twitter.com/hashtag/PrecisionMedicine?src=hash&amp;ref_src=twsrc%5Etfw">#PrecisionMedicine</a> <a href="https://t.co/Eac5EzZmbk">https://t.co/Eac5EzZmbk</a> <a href="https://t.co/0NmQSkMPJg">pic.twitter.com/0NmQSkMPJg</a>
&mdash; Dr. Thomas Wilckens (@Thomas_Wilckens) <a href="https://twitter.com/Thomas_Wilckens/status/1016687526734688256?ref_src=twsrc%5Etfw">July 10, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&nbsp;They assessed&nbsp;peripheral blood cells from 95 individuals that were obtained, on average,&nbsp;6.3 years before&nbsp;AML diagnosis (pre-AML group) and compared the findings with&nbsp;414 unselected age- and gender-matched individuals (control group).&nbsp;They found that pre-AML cases were distinct from controls and&nbsp;had more mutations per sample and higher variant allele frequencies.&nbsp;ARCH&nbsp;(based on putative driver mutations) was found in 73.4% of the pre-AML cases at a median of 7.6 years prior to diagnosis&nbsp;compared with 36.7% of controls.&nbsp;The researchers&nbsp;said they were surprised by this long lead time,&nbsp;as the disease&nbsp;often appears&nbsp;suddenly.&nbsp;The&nbsp;model was validated in an independent cohort of 29 pre-AML cases and 262 controls.&nbsp;<a href="https://proddocwire.wpengine.com/hematology-oncology/children-with-ambiguous-leukemia-fare-better-with-lymphoid-directed-treatment/">Read about how children with ambiguous leukemia fare better with lymphoid-directed treatment.</a>&nbsp;&nbsp;Source:&nbsp;<a href="https://www.nature.com/articles/s41586-018-0317-6">Cancer&nbsp;</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Can AML Be Predicted and Prevented Years in Advance?

Oncology

A proof-of-concept study published in Nature found that there may be identifiable mutations in healthy individuals who are at high risk of developing acute myeloid ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe